480nm operates at the skin surface, targeting porphyrins produced by C. acnes bacteria. When these porphyrins absorb blue light, they generate reactive oxygen species that destroy the bacteria from within — a clinically validated mechanism for acne treatment. 480nm also activates the OPN3 (Opsin-3) photoreceptor in melanocytes, which is why it requires careful management in Fitzpatrick III–VI skin tones.

590nm is the dedicated pigmentation wavelength — and the most underrepresented in the LED device market despite having strong clinical evidence. It inhibits tyrosinase (the enzyme that produces melanin), induces autophagy to clear existing melanin deposits, and suppresses VEGF and SCF — the vascular signals that drive melasma. A 2022 study published in Cells confirmed that 590nm LED significantly attenuated erythema and hyperpigmentation in melasma patients by targeting the vascular-pigmentation link simultaneously. It also boosts lymphatic drainage and microcirculation for a visible detox glow.

630nm drives collagen scaffolding in the upper dermis — the layer most visible in skin texture and tone. It stimulates fibroblast activity near the surface, producing new collagen at a depth that creates visible improvements in fine lines, pore size and overall smoothness faster than deeper wavelengths. With nearly 1,000 studies in the literature (630–633nm range), it is one of the best-evidenced wavelengths in photobiomodulation. It sits just outside the CCO absorption peak but has sufficient absorption to drive meaningful mitochondrial responses in superficial tissue.

660nm is the peak absorption wavelength for Cytochrome C Oxidase — the primary photoreceptor in mitochondria and the dominant target in photobiomodulation science. At this wavelength, the CCO enzyme absorbs photons most efficiently, triggering the largest boost in mitochondrial ATP production. The downstream effects include maximum collagen and elastin synthesis, accelerated wound healing, reduced pro-inflammatory cytokines and protection against oxidative stress. With 943 studies in the literature, 660nm is the most researched wavelength in the field and the gold standard for skin rejuvenation, anti-aging and inflammation reduction.

670nm sits slightly outside the CCO peak but has a disproportionately strong evidence base — particularly in neurological and retinal research. It is the most-studied wavelength for ocular applications (64 studies), with pioneering work by Glen Jeffery at University College London demonstrating that 670nm improves retinal function and photoreceptor mitochondrial activity in ageing eyes. 670nm also appears prominently in brain research alongside 810nm. For body applications, it maximises ATP production and supports deep cellular respiration — linked to metabolic energy boost and neuroprotective effects. Penetrates slightly deeper than 660nm while remaining within the CCO absorption range.

810nm is the leading wavelength for transcranial photobiomodulation — the application of NIR light to the brain. It creates what researchers describe as an "optical window" through skull tissue, allowing photons to reach cortical neurons directly. With 1,205 studies in the literature (808–810nm range), it is the most-studied NIR wavelength overall. Clinical research demonstrates improvements in cognitive function, neuroprotection, memory, mood and recovery from traumatic brain injury. At 40Hz pulse frequency, 810nm is associated with gamma brain wave entrainment linked to cognitive enhancement and Alzheimer's prevention research. For body applications, it is highly effective for deep tissue penetration in large muscle groups and joint structures.

830nm is the deep connective tissue wavelength — reaching tendons, ligaments and joint capsules that red wavelengths and even 850nm cannot fully access. With 624 studies in the literature, it ranks 4th by study count across all wavelengths. Research specifically identifies 830nm as effective for structural repair in deep connective tissue: reducing inflammation in tendinitis, supporting collagen remodelling in damaged ligaments and improving range of motion in stiff joints. A 6-week trial comparing 830nm directly to 1064nm LED therapy for joint conditions confirmed its deep structural efficacy. It also has well-established evidence for dental and wound healing applications.

850nm is the gold standard wavelength for muscle recovery — the most-evidenced wavelength for post-exercise DOMS reduction, with 68 studies specifically in the muscle category. It penetrates 30–40mm directly into muscle belly tissue, boosting mitochondrial ATP production in muscle fibres and reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) that drive delayed onset soreness. A 2025 meta-analysis of 14 controlled studies confirmed significant DOMS reduction at 24 hours post-exercise versus placebo. For joints, 850nm supports collagen type II synthesis and glycosaminoglycan production in cartilage — making it effective for osteoarthritis. It also leads all wavelengths in sleep research with 6 dedicated studies.

1060nm is the most clinically unique wavelength in the Lumnae panel range — and the most differentiated from what most LED devices offer. It is the only wavelength with peer-reviewed clinical evidence for direct fat cell metabolism through specific lipid absorption. At 1060nm, photons induce the formation of transient pores in adipocyte membranes, facilitating triglyceride release and activating hormone-sensitive lipase pathways — the mechanism of lipolysis. A 2021 study published in Aesthetic Surgery Journal confirmed the safety and efficacy of 1060nm for non-invasive fat reduction of the abdomen. A 2025 clinical evaluation of 60 patients confirmed good efficacy and visible aesthetic results at 3-month follow-up, with skin temperature remaining below 40°C throughout — confirming the safety profile at LED irradiance levels. 1060nm also provides the deepest thermal support for chronic tissue — reaching joint capsules and periarticular structures of deep joints (hips, knees) that other wavelengths cannot effectively access.